Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) and Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
Volatility and Risk
Autolus Therapeutics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Institutional & Insider Ownership
72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Autolus Therapeutics | $10.09 million | 59.33 | -$208.38 million | ($1.21) | -1.86 |
Anavex Life Sciences | N/A | N/A | -$47.51 million | ($0.50) | -21.74 |
Anavex Life Sciences has lower revenue, but higher earnings than Autolus Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Autolus Therapeutics and Anavex Life Sciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Autolus Therapeutics | N/A | -63.65% | -36.54% |
Anavex Life Sciences | N/A | -30.64% | -28.23% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Autolus Therapeutics and Anavex Life Sciences, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Autolus Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
Anavex Life Sciences | 0 | 0 | 2 | 1 | 3.33 |
Autolus Therapeutics currently has a consensus target price of $10.40, suggesting a potential upside of 362.22%. Anavex Life Sciences has a consensus target price of $43.00, suggesting a potential upside of 295.58%. Given Autolus Therapeutics’ higher possible upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Anavex Life Sciences.
Summary
Autolus Therapeutics beats Anavex Life Sciences on 7 of the 13 factors compared between the two stocks.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.